Skip to Content
  • A New Look at Clinical Success Rates

    Andrew Lo of MIT and his co-workers have published a really interesting paper on clinical trial probability-of-success numbers. It appears to be the largest suc… Read More
  • Scaffold Popularity

    Here’s a paper that’s analyzing the popularity of different structural scaffolds in medicinal chemistry over time. The authors are using the ChEMBL… Read More
  • More Movements at the Top of GSK

    GlaxoSmithKline has been having more than its share of ups and downs over the last few years. In 2014, they moved a lot of assets out of oncology, as part of a… Read More
  • The Drug Project Landscape

    Here’s a new paper in Nature Reviews Drug Discovery that’s going to the trouble of matching specific disease indications with specific mechanisms in… Read More
  • Whole Classes of Things

    We all know about target-based drug discovery. Enough biology has been learned that we think that Protein X is operating at a crucial stage in the development o… Read More
  • Alnylam Breaks Through

    As a pioneer in RNAi therapeutics, Alnylam has really had some ups and downs over the years (some of them chronicled on this blog). Today would be one of the &# Read More
  • Where MRSA Came From

    OK, everyone recognizes the problem that we face with drug-resistant bacteria. MRSA (methicillin-resistant Staphylococcus aureus) is the most well-known variety… Read More
Page 1 of 3912345...102030...Last »